Published Studies Related to Alkeran Injection (Melphalan Injection)
Well-designed clinical trials related to Alkeran Injection (Melphalan Injection)
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. [2011.05]
Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112. [2011.04]
Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. [2011.04]
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. [2011.01]
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. [2011.01]
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. [2010.12.01]
The NK receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. [2010.12]
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. [2010.11.11]
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. [2010.10.15]
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. [2010.10]
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. [2010.09.02]
Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. [2010.08]
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. [2010.07.01]
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. [2010.05.01]
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. [2010.03.11]
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. [2010.02.11]
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. [2009.12.20]
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. [2009.08.01]
The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93. [2009.05.15]
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. [2009.04.09]
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. [2008.10.15]
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. [2008.08.28]
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trial. [2008.05.27]
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. [2007.10.06]
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. [2007.09.13]
A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. [2007.01]
Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. [2006.11]
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. [2006.09.01]
A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. [2006.06]
Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). [2006.04]
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. [2006.03.11]
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. [2006.02.15]
Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation. [2006.02]
Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. [1995.10]
Gut protection by cyclophosphamide "priming" in patients receiving high-dose melphalan--effect of drug scheduling. [1992]
Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central Sweden. [1990]
Well-designed clinical trials possibly related to Alkeran Injection (Melphalan Injection)
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. [2011.08.04]
Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. [2011.06]
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. [2011.01.13]
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. [2010.12.02]
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. [2010.12.01]
Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group. [2010.08.01]
Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. [2010.06]
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL. [2010.04]
A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma. [2010.01]
Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. [2009.04.10]
Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial. [2009.04]
ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. [2009.02.10]
EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells. [2009.02]
Cytotoxicity of 1-aryl-3-buthylamino-1-propanone hydrochlorides against Jurkat and L6 cells. [2009]
Standard therapy of advanced Hodgkin lymphoma. [2009]
Immunoadsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCV-related cryoglobulinemia. [2009]
Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group. [2008.12.15]
Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial. [2008.11.10]
Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. [2008.11]
High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. [2008.03]
Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group. [2008.03]
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. [2008.03]
Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. [2007.09.20]
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. [2007.06.10]
Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. [2007.02]
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group. [2007.01]
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). [2007.01]
Dose Dense (CEOP-14) vs Dose Dense and Rituximab (CEOP-14 +R) in High-Risk Diffuse Large Cell Lymphoma. [2007]
Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. [2006.05.01]
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. [2006.05.01]
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. [2006.05]
Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. [2006.05]
Circulating levels and clinical significance of soluble CD86 in myeloma patients. [2006.04]
Thalidomide and hematopoietic-cell transplantation for multiple myeloma. [2006.03.09]
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. [2006.02.20]
MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors. [2006.01.15]
Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. [2006.01.01]
Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial. [2003.08]
Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial. [1997.05.01]
Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas. [1997.05]
Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy. [1994.09]
Recombinant interferon-alpha 2A as maintenance treatment for patients with advanced stage chronic lymphocytic leukemia responding to chemotherapy. [1992.09]
Intraperitoneal radioactive phosphate in early ovarian carcinoma: an analysis of complications. [1991.05]
Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy. [1991]
Other research related to Alkeran Injection (Melphalan Injection)
Synergistic inhibition of malignant melanoma proliferation by melphalan combined with ultrasound and microbubbles. [2011.09]
Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy
followed by prednisolone/interferon maintenance therapy for multiple myeloma:
Japan Clinical Oncology Group Study, JCOG0112. [2011]
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly
and/or transplant ineligible patients with multiple myeloma: a meta-analysis. [2011]
Addition of thalidomide to oral melphalan/prednisone in patients with multiple
myeloma not eligible for transplantation: results of a randomized trial from the
Turkish Myeloma Study Group. [2011]
Preclinical comparison of intravenous melphalan pharmacokinetics administered in formulations containing either (SBE)7 m-beta-cyclodextrin or a co-solvent system. [2010.11]
A Phase I/II Trial Combining High Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study. [2010.08.25]
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. [2010.08.23]
Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. [2010.07.29]
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. [2010.06]
Long-term survival of a phase I clinical trial of isolated lung perfusion with melphalan for resectable lung metastases. [2010.05.15]
Supraselective injection of intraarterial melphalan as the primary treatment for late presentation unilateral multifocal stage Vb retinoblastoma. [2010.04]
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with
bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial
treatment of multiple myeloma: a randomized controlled trial. [2010]
A phase I/II trial combining high-dose melphalan and autologous transplant with
bortezomib for multiple myeloma: a dose- and schedule-finding study. [2010]
Phase III study of the value of thalidomide added to melphalan plus prednisone in
elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. [2010]
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone
in previously untreated multiple myeloma: updated follow-up and impact of
subsequent therapy in the phase III VISTA trial. [2010]
Management of isolated nonresectable liver metastases in colorectal cancer
patients: a case-control study of isolated hepatic perfusion with melphalan
versus systemic chemotherapy. [2010]
A randomized phase 3 study on the effect of thalidomide combined with adriamycin,
dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in
patients with multiple myeloma. [2010]
[The significance and function of IFN-gamma on the changes of peripheral blood platelet count during tumor-rejection induced by a low dose of melphalan in C57BL/6 mice] [2009.11]
Hyperthermic Isolated Limb Perfusion in Locally Advanced Soft Tissue Sarcoma and Progressive Desmoid-Type Fibromatosis with TNF 1 mg and Melphalan (T1-M HILP) Is Safe and Efficient. [2009.10.15]
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. [2009.08.10]
Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). [2009.07.20]
|
